At the ESH 11th Translational Research Conference: Myeloproliferative Neoplasms, April 24–26, 2026, Estoril, PT, the MPN Hub held a symposium, titled Patient-centered approaches in myelofibrosis: Tailoring treatment for anemia and thrombocytopenia. During the symposium, MPN Hub Steering Committee member Steffen Koschmieder, Uniklinikum RWTH Aachen, Aachen, DE, delivered a presentation on navigating therapeutic options for patients with cytopenic myelofibrosis.

In this presentation, Koschmieder discusses current therapeutic approaches to cytopenic MF, including a review of key data on outcomes with momelotinib, pacritinib, luspatercept, and pelabresib and selinexor in combination with ruxolitinib.

This educational resource is independently supported by GSK. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence

Hosted on Acast. See acast.com/privacy for more information.

Hello, and welcome to our podcast. Today, Jean-Jacques Kiladjian, Consultant Hematologist from the Université Paris Cité - Hôpital Saint-Louis, Paris, France, discusses cytopenias in myelofibrosis, with a focus on clinical burden and the need for prioritized management.

This educational resource is independently supported by GSK. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.

At the ESH 11th Translational Research Conference: Myeloproliferative Neoplasms, April 24–26, 2026, Estoril, PT, the MPN Hub held a symposium, titled Patient-centered approaches in myelofibrosis: Tailoring treatment for anemia and thrombocytopenia. During the symposium, MPN Hub Steering Committee member Claire Harrison, Guy's and St Thomas' NHS Foundation Trust, London, UK, delivered a presentation on treatment options for patients with cytopenic myelofibrosis (MF), reviewing treatment algorithms and providing real‑world insights.

In this presentation, Harrison discusses the impact of transfusions on patients with MF and MF subgroups, as well as the British Society for Haematology (BSH) 2024 and National Comprehensive Cancer Network (NCCN) 2026 guidelines for managing cytopenia in patients with MF. She also reviews real-world evidence for current treatment options, using patient cases to illustrate treatment selection in the clinical setting.

This educational resource is independently supported by GSK. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.